Skip to main content
QURE
NASDAQ Life Sciences

UniQure 报告 2025 年每股亏损 $3.46

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$9.2
Mkt Cap
$962.867M
52W Low
$7.76
52W High
$71.5
Market data snapshot near publication time

summarizeSummary

uniQure N.V. 宣布 2025 年全年每股亏损 $3.46。这份财务更新为公司的运营表现和盈利能力提供了关键的洞察，这也是投资者关注的关键指标。虽然时间线显示最近的 SEC 文件和集体诉讼，但这份具体的收益结果是新的信息。每股亏损较大可能会对投资者情绪产生负面影响，并对股票施加压力，尤其是对于处于开发阶段的生物技术公司。交易者将密切关注有关此亏损的驱动因素的进一步细节以及管理层的前瞻性指导。

在该公告发布时，QURE的交易价格为$9.20，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9.6亿。 52周交易区间为$7.76至$71.50。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed QURE - Latest Insights

QURE
Apr 27, 2026, 7:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Significant Share Issuance Authority and Capital Increase Amidst Clinical Setbacks
Sentiment: Negative
View Wiseek Article
QURE
Apr 16, 2026, 5:00 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Shareholders to Vote on Significant Share Issuance Authority and Capital Increase Amidst Clinical Setbacks
Sentiment: Negative
View Wiseek Article
QURE
Mar 23, 2026, 9:40 PM EDT
Source: Access Newswire
Importance Score:
8
Securities Fraud Lawsuit Filed Against uniQure N.V. Over 49% Stock Drop Following FDA Approval Delay
Sentiment: Negative
View Wiseek Article
QURE
Mar 03, 2026, 5:30 AM EST
Source: Dow Jones Newswires
Importance Score:
8
FDA's Stricter Accelerated Approval Process Creates 'Chaos' for Rare Disease Biotech, uniQure Plunges 33%
Sentiment: Negative
View Wiseek Article
QURE
Mar 02, 2026, 7:24 AM EST
Filing Type: 10-K
Importance Score:
9
FDA Rejects Lead Gene Therapy BLA Pathway, Recommends New Trial; Other Programs Face Setbacks
Sentiment: Negative
View Wiseek Article
QURE
Mar 02, 2026, 7:09 AM EST
Source: Dow Jones Newswires
Importance Score:
8
UniQure Reports $3.46 Per Share Loss for 2025
Sentiment: Negative
View Wiseek Article
QURE
Mar 02, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
9
FDA Rejects AMT-130 Phase I/II Data for Marketing Application, Recommends Phase III Study
Sentiment: Negative
View Wiseek Article
QURE
Feb 26, 2026, 9:20 PM EST
Source: Acceswire
Importance Score:
7
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Sentiment: Negative
View Wiseek Article
QURE
Jan 13, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
uniQure Reports Positive 36-Month Phase I/II Data for AMT-130 in Huntington's Disease
Sentiment: Positive
View Wiseek Article
QURE
Jan 09, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
uniQure Schedules Key FDA Type A Meeting for AMT-130 Accelerated Approval Pathway
Sentiment: Neutral
View Wiseek Article